已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

地塞米松 医学 多发性骨髓瘤 内科学 来那度胺 耐火材料(行星科学) 肿瘤科 天体生物学 物理
作者
Jin Lu,Liangquan Geng,Lijuan Chen,Peng Liu,Yuping Zhong,Zhuogang Liu,Zhongjun Xia,Jian‐Qing Mi,Chunrui Li,Xi Zhang,Yanjuan He,Yongqiang Wei,Baijun Fang,Fei Li,Zhen Cai,Yafei Wang,Dongping Huang,Hong Liu,Ming Hou,Rong Fu
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 4748-4748 被引量:5
标识
DOI:10.1182/blood-2024-202893
摘要

Introduction: Selinexor (ATG-010) is a first-in-class, orally bioavailable XPO1 inhibitor which binds to exportin 1, inhibiting nuclear export of tumor suppressor proteins. It synergizes with proteasome inhibitors (PIs) in preclinical studies and produces high response rates in patients (pts) with PI refractory and non-refractory MM. In the global phase 3 BOSTON study (NCT03110562), SVd significantly improved progression free survival (PFS), compared to twice weekly Vd [harzard ratio (HR) 0.70)]. The China registrational bridging study, BENCH (NCT04939142) aimed to demonstrate the consistency of efficacy and safety outcomes between these 2 studies. Methods: This phase 3, randomized, open label, study was conducted at 33 sites in China. The adult pts with RRMM, who had previously been treated with 1 to 3 lines of therapy, were randomly allocated (2:1) to receive SVd: selinexor (100 mg once per week), bortezomib (1.3mg/m2 once per week) and dexamethasone (20 mg twice per week), or Vd: bortezomib (1.3mg/m2 twice per week for the first 24 weeks and once per week thereafter) and dexamethasone (20 mg four times per week for the first 24 weeks and twice per week thereafter). Pts receiving Vd could cross over to either SVd or Sd treatment after confirmation of progression. The primary endpoint was PFS in the intention-to-treat (ITT) population. The key secondary endpoints included ORR (≥PR), response rate of ≥VGPR and the incidence of Grade ≥2 peripheral neuropathy (PN). Efficacy was assessed by independent review committee per IMWG 2016. The PFS HR should reach less than 0.85 to show consistency (at least 50% efficacy with BOSTON study). Results: As of 9th May 2024, a total of 154 Chinese RRMM pts were randomized to SVd group (n=101) or Vd group (n=53) and 152 pts received at least one dose of study drug (safety population). The baseline demographic and clinical characteristics were approximately balanced across the two treatment groups. The median age was 62 (range: 33-78). 87 pts (56.5%) were male and 67 pts (43.5%) were female. R-ISS stage III and high-risk cytogenetic abnormalities (including del(17p), t(14;16), t(4;14), 1q21) were present in 18 (11.7%) and 105 (68.2%) pts, respectively. However, SVd group included more pts with extramedullary disease than Vd group [24 (23.8%) vs 4 (7.5%)]. At a median follow-up time of 20.6 months (range:10.2-33.4), the median PFS was 8.1 months with SVd group and 6.3 months with Vd group. The HR reached 0.74 (95% CI 0.48-1.15; P=0.180). A similar reduction in the risk of progression was observed for SVd group between BENCH and BOSTON study. The ORR was higher in SVd group than in Vd group (72.3% vs 62.3%, P=0.173). SVd group had a significantly higher proportion of pts with response of VGPR or better (45.5% vs 22.6%, P=0.005). Among pts with response of CR or better, 59% (13/22) vs 25% (1/4) (SVd vs Vd) achieved MRD negativity (<1x10-5). The median time to response and the median duration of response were 0.8 vs 1.4 months and 9.7 vs 7.2 months (SVd vs Vd) respectively. The median overall survival was not reached in both groups. The most frequent Grade 3-4 adverse events (AEs) for SVd and Vd (≥10%) were thrombocytopenia (55.0% vs 28.8%), lymphocytopenia (37.0% vs 17.3%), anemia (25% vs 17.3%), neutropenia (17.0% vs 3.8%), pneumonia (14.0% vs 13.5%), cataract (13.0% vs 0%), diarrhea (6.0% vs 15.4%) and hypokalemia (8.0% vs 11.5%). The incidence of Grade≥2 PN was significantly lower in SVd than in Vd group (8% vs 32.7%, P=0.001). Conclusion: SVd regimen decreased the risk of progression and obtained much more profound responses compared to standard Vd regimen in Chinese pts with RRMM. The incidence of Grade ≥2 PN were significantly reduced. The results of BENCH study were consistent with the BOSTON study despite differences in patient populations and the primary end point achieved.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
高高云朵完成签到 ,获得积分10
刚刚
爱听歌的代曼完成签到 ,获得积分10
2秒前
FOD完成签到 ,获得积分10
2秒前
CoCo完成签到 ,获得积分10
2秒前
2秒前
2秒前
yangl完成签到 ,获得积分10
2秒前
简云铃完成签到,获得积分10
3秒前
坚强梦菲完成签到 ,获得积分10
4秒前
知性的水蜜桃完成签到 ,获得积分10
5秒前
慕青的应助被这样说话采纳,获得10
6秒前
111发布了新的文献求助10
7秒前
典雅狐狐完成签到,获得积分20
8秒前
wenjing完成签到 ,获得积分10
9秒前
典雅狐狐发布了新的文献求助50
18秒前
18秒前
机灵的以莲完成签到,获得积分10
20秒前
英俊的铭的应助被啊啊啊采纳,获得10
21秒前
Chem完成签到,获得积分10
24秒前
boogiepop完成签到,获得积分10
25秒前
26秒前
1733135296完成签到,获得积分10
26秒前
30秒前
henan完成签到,获得积分10
34秒前
爱you发布了新的文献求助10
35秒前
39秒前
loii举报小面包的求助涉嫌违规
40秒前
42秒前
nanfeng完成签到 ,获得积分10
43秒前
43秒前
loii举报不安迎海的求助涉嫌违规
43秒前
风中的芷珍完成签到,获得积分10
44秒前
桐桐的应助被奇迹采纳,获得10
46秒前
啊啊啊发布了新的文献求助10
47秒前
llllll完成签到 ,获得积分10
47秒前
洁净凡波完成签到,获得积分10
48秒前
zs发布了新的文献求助10
48秒前
典雅狐狐关注了科研通微信公众号
49秒前
喻永卓完成签到,获得积分10
50秒前
呆呆的猕猴桃完成签到 ,获得积分10
50秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179592
求助须知:如何正确求助?哪些是违规求助? 9569910
关于积分的说明 21807526
捐赠科研通 7775056
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478760